Category: Pharmaceuticals
Suzhou Alphamab Co. and Ascletis Pharma Inc. together announced that Alphamab and the subsidiary of Ascletis have signed an exclusive licensing agreement and entered into a strategic collaboration for …
The National Institute for Health and Care Excellence (NICE), the public body under the Department of Health in England, has reportedly rejected Novartis’ migraine treatment drug Aimovig (erenumab). As …
Lupin Limited has reportedly received the European Commission’s approval for its specialty drug NaMuscla used in the treatment of a rare neuromuscular disorder. As per trusted sources, Lupin is …
The investment will be used to fund the development of Antengene’s lead ATG-010 (selinexor), ATG-008 programs and clinical-stage assets. Renowned clinical-stage biopharmaceutical company, Antengene Corp. has recently completed a $120 …
Gala Pharmaceutical California Inc., which is a subsidiary of Gala Pharmaceutical, Inc., has recently announced that it has been granted a Temporary License by the State of California for …
Dr. Reddy’s Laboratories Ltd., an Indian multinational pharmaceutical company in Hyderabad, has reportedly declared the launch of the oral suspension drug Sevelamer Carbonate in the U.S. market. Sources claim …
BrainStorm Cell Therapeutics, a biotechnology company that is engaged in the development of autologous stem cell therapies, recently announced that it would be expanding its autologous cell manufacturing capacity …
The partnership will intend to pursue development across a range of hematological cancers, many with inadequate treatment options India’s renowned pharmaceutical firm, Lupin Ltd. has recently announced its collaboration with U.S. …
Walgreens Boots Alliance, the global health and well being enterprise, recently announced along with Alphabet’s life sciences unit Verily that the companies will be collaborating on improving outcomes for patients …
TheKEYTRUDA® is developed for the treatment of Metastatic or recurrentlocally-advanced or merkel-cell carcinoma (MCC) in adult as well as pediatricpatients. Theapproval is based upon the drug’s objective response rate …
